Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease

Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role i...

Full description

Bibliographic Details
Main Authors: Cai-Mei Zheng, Yung-Ho Hsu, Chia-Chao Wu, Chien-Lin Lu, Wen-Chih Liu, Jing-Quan Zheng, Yuh-Feng Lin, Hui-Wen Chiu, Tian-Jong Chang, Jia-Fwu Shyu, Kuo-Cheng Lu
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/20/11/2800
id doaj-5d3c306c882340dfae654fe880c0fec4
record_format Article
spelling doaj-5d3c306c882340dfae654fe880c0fec42020-11-25T01:14:03ZengMDPI AGInternational Journal of Molecular Sciences1422-00672019-06-012011280010.3390/ijms20112800ijms20112800Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney DiseaseCai-Mei Zheng0Yung-Ho Hsu1Chia-Chao Wu2Chien-Lin Lu3Wen-Chih Liu4Jing-Quan Zheng5Yuh-Feng Lin6Hui-Wen Chiu7Tian-Jong Chang8Jia-Fwu Shyu9Kuo-Cheng Lu10Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanDivision of Nephrology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei 10581, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, TaiwanSecondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.https://www.mdpi.com/1422-0067/20/11/2800cinacalcetrenal osteodystrophyosteoclastWnt 10bchronic kidney disease
collection DOAJ
language English
format Article
sources DOAJ
author Cai-Mei Zheng
Yung-Ho Hsu
Chia-Chao Wu
Chien-Lin Lu
Wen-Chih Liu
Jing-Quan Zheng
Yuh-Feng Lin
Hui-Wen Chiu
Tian-Jong Chang
Jia-Fwu Shyu
Kuo-Cheng Lu
spellingShingle Cai-Mei Zheng
Yung-Ho Hsu
Chia-Chao Wu
Chien-Lin Lu
Wen-Chih Liu
Jing-Quan Zheng
Yuh-Feng Lin
Hui-Wen Chiu
Tian-Jong Chang
Jia-Fwu Shyu
Kuo-Cheng Lu
Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
International Journal of Molecular Sciences
cinacalcet
renal osteodystrophy
osteoclast
Wnt 10b
chronic kidney disease
author_facet Cai-Mei Zheng
Yung-Ho Hsu
Chia-Chao Wu
Chien-Lin Lu
Wen-Chih Liu
Jing-Quan Zheng
Yuh-Feng Lin
Hui-Wen Chiu
Tian-Jong Chang
Jia-Fwu Shyu
Kuo-Cheng Lu
author_sort Cai-Mei Zheng
title Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
title_short Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
title_full Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
title_fullStr Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
title_full_unstemmed Osteoclast-Released Wnt-10b Underlies Cinacalcet Related Bone Improvement in Chronic Kidney Disease
title_sort osteoclast-released wnt-10b underlies cinacalcet related bone improvement in chronic kidney disease
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2019-06-01
description Secondary hyperparathyroidism (SHPT) relates to high turnover bone loss and is responsible for most bone fractures among chronic kidney disease (CKD) patients. Changes in the Wingless/beta-catenin signaling (Wnt/β-catenin) pathway and Wnt inhibitors have been found to play a critical role in CKD related bone loss. A calcimimetic agent, cinacalcet, is widely used for SHPT and found to be similarly effective for parathyroidectomy clinically. A significant decrease in hip fracture rates is noted among US hemodialysis Medicare patients since 2004, which is probably related to the cinacalcet era. In our previous clinical study, it was proven that cinacalcet improved the bone mineral density (BMD) even among severe SHPT patients. In this study, the influence of cinacalcet use on bone mass among CKD mice was determined. Cinacalcet significantly reduced the cortical porosity in femoral bones of treated CKD mice. It also improved the whole-bone structural properties through increased stiffness and maximum load. Cinacalcet increased femoral bone wingless 10b (Wnt10b) expression in CKD mice. In vitro studies revealed that cinacalcet decreased osteoclast bone resorption and increased Wnt 10b release from osteoclasts. Cinacalcet increased bone mineralization when culturing the osteoblasts with cinacalcet treated osteoclast supernatant. In conclusion, cinacalcet increased bone quantity and quality in CKD mice, probably through increased bone mineralization related with osteoclast Wnt 10b secretion.
topic cinacalcet
renal osteodystrophy
osteoclast
Wnt 10b
chronic kidney disease
url https://www.mdpi.com/1422-0067/20/11/2800
work_keys_str_mv AT caimeizheng osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT yunghohsu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT chiachaowu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT chienlinlu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT wenchihliu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT jingquanzheng osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT yuhfenglin osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT huiwenchiu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT tianjongchang osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT jiafwushyu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
AT kuochenglu osteoclastreleasedwnt10bunderliescinacalcetrelatedboneimprovementinchronickidneydisease
_version_ 1725159199405506560